论文部分内容阅读
背景:尼莫地平作为钙离子拮抗剂已广泛用于蛛网膜下腔出血,但对高血压脑出血患者神经功能及生活能力改善的作用以及对神经元特异性烯醇化酶(neuron-spicificenolase,NSE)的影响客观研究不足。目的:观察高血压脑出血患者使用尼莫地平后患者神经功能及生活能力的恢复以及对血浆NSE的影响。设计:随机对照试验研究。单位:四川省人民医院神经内科。对象:1997-10/1999-03住四川省人民医院神经内科的85例高血压脑出血患者,入院时发病时间不超过24h,经头颅CT证实为脑实质出血,血肿均小于40mL。患肿瘤、原发性脑室出血、继发性蛛网膜下腔出血、混合性脑卒中或其他神经系统疾病的患者排除在外。方法:85例高血压脑出血患者随机分为对照组和尼莫地平治疗组,动态观察患者神经功能缺损程度和总的生活能力评分,血浆NSE水平及血肿体积。主要观察指标:两组患者神经功能缺损程度;总的生活能力评分;血浆NSE水平。结果:尼莫地平治疗组与对照组的临床神经功能缺损程度及生活能力评分在病程第14天时差异无显著性意义(P>0.05),在第30,90天时治疗组的神经功能(77.91±42.46,85.03±45.95)。恢复优于对照组(65.21±35.74,73.02±40.12),差异有显著性意义,两组患者的血浆NSE水平在各个时间点上差异无显著性意义(P>0.05)。结论:脑出
BACKGROUND: Nimodipine, as a calcium antagonist, has been widely used in subarachnoid hemorrhage, but has no effect on neurological function and viability in patients with hypertensive intracerebral hemorrhage. Neuromuscular blockade of neuron-specific immunolanse (NSE ) The impact of objective research is not enough. Objective: To observe the recovery of neurological function and viability of patients with hypertensive intracerebral hemorrhage after nimodipine treatment and the effect on plasma NSE. Design: Randomized controlled trial. Unit: Department of Neurology, Sichuan Provincial People’s Hospital. PARTICIPANTS: From October 1997 to March 1999, 85 patients with hypertensive intracerebral hemorrhage who lived in Department of Neurology, People’s Hospital of Sichuan Province were admitted to hospital for less than 24 hours. All patients were confirmed as cerebral parenchymal hemorrhage by CT. Patients with tumors, primary ventricular hemorrhage, secondary subarachnoid hemorrhage, mixed strokes or other neurological disorders are excluded. Methods: Eighty-five patients with hypertensive intracerebral hemorrhage were randomly divided into control group and nimodipine treatment group. The degree of neurological deficit, total life ability score, plasma NSE level and hematoma volume were dynamically observed. MAIN OUTCOME MEASURES: The degree of neurological deficit in both groups; total viability score; plasma NSE levels. Results: There was no significant difference between the nimodipine treatment group and the control group in the clinical neurological deficit score and the viability score on the 14th day (P> 0.05). At the 30th and 90th days, the neurological function (77.91 ± 42.46, 85.03 ± 45.95). The recovery was superior to the control group (65.21 ± 35.74, 73.02 ± 40.12), the difference was statistically significant. There was no significant difference in plasma NSE levels between the two groups at all time points (P> 0.05). Conclusion: Brain out